Jinan Zhuocheng Bio-Tech Co., Ltd.

Currently, the global veterinary drug and animal health industry is characterized by a distinct pattern of “three leading hubs, multi-point development, and ecosystem-based competition and cooperation.” North America, Europe, and East Asia serve as the three core regions driving industry development. Each regional cluster relies on differentiated product strengths, systematic policy support, and full-chain services to continuously reshape the global competitive landscape of veterinary drug innovation.

As the global veterinary pharmaceutical industry accelerates toward intelligent, collaborative, and international development, leading clusters have accumulated mature experiences worth learning from, while also revealing common issues that warrant attention.

I. Success Experiences: Four High-Quality Development Pathways

1. Building an Integrated Innovation Ecosystem of “Basic Research – Clinical Translation – Industrial Application”

Taking the Boston–Cambridge innovation corridor in the United States as an example, its success lies in establishing a complete chain from upstream innovation to commercialization.

Upstream, world-class institutions such as the Broad Institute drive breakthroughs in foundational technologies such as gene editing.
Midstream, affiliated clinical networks of Harvard Medical School enable efficient clinical validation.
Downstream, companies such as Moderna and Editas Medicine achieve large-scale industrialization, forming a highly efficient “triangle” of research, clinical practice, and industry collaboration.

For veterinary pharmaceutical companies, this implies the need to build an integrated end-to-end collaboration system covering laboratory R&D, field trials, and large-scale production.

2. Efficient Synergy Between Government-Led Funds and Market-Based Patient Capital

The Bavarian region in Germany focuses on early-stage innovation in the biopharmaceutical industry. Supported by a government-backed early investment system, it leverages fiscal capital to crowd in private investment through a “invest early, invest small” strategy, targeting seed and early-stage projects.

The system adopts a long-term exit mechanism of 7–10 years, reducing emphasis on short-term returns and prioritizing long-term survival and growth quality of small and medium-sized enterprises. This has established a patient capital ecosystem aligned with industry development cycles.

The Munich biotech cluster, supported by this framework, has rapidly advanced in cutting-edge areas such as mRNA vaccines and AI-driven drug discovery, while forming industrial synergy with companies such as Pfizer and BioNTech.

Veterinary pharmaceutical companies may draw from this model by seeking long-term capital support to sustain extended R&D cycles.

3. Balancing International Regulatory Standards with Localized Service Support

Singapore’s Biopolis adheres to a “global standards, local adaptation” positioning and has built a highly internationalized industrial ecosystem.

The park fully aligns with FDA and EMA regulatory requirements and has established GLP- and GMP-compliant R&D and production facilities with internationally recognized certifications, supporting global R&D, regulatory submissions, and manufacturing.

At the same time, it has introduced leading global CRO/CDMO companies such as Charles River and Lonza to provide integrated outsourcing services, significantly improving R&D efficiency.

In terms of localized services, it provides full English-language administrative services covering compliance, legal affairs, tax planning, and intellectual property protection.

Veterinary export enterprises should place strong emphasis on GMP certification, GLP compliance, and veterinary drug registration requirements in target markets.

4. Promoting Free Talent Mobility and Deep Cross-Disciplinary Integration

The innovation vitality of leading global clusters is driven by open talent mobility and deep interdisciplinary integration.

The Cambridge cluster in the UK, centered on the University of Cambridge, has built interdisciplinary collaboration platforms such as translational medicine centers and implemented a “professor entrepreneurship” mechanism, allowing researchers to retain academic positions while founding companies, thereby fully releasing innovation and commercialization potential.

In Massachusetts, industrial expansion has driven talent aggregation. From 2009 to 2019, employment in the biopharmaceutical sector increased by 35%, adding nearly 20,000 jobs, more than 60% of which were concentrated in the Boston area, mainly in drug discovery and clinical translation.

The veterinary pharmaceutical industry also requires collaborative innovation among experts in veterinary medicine, pharmacy, and data science.

II. Risk Warnings: Three Key Lessons

1. Overreliance on a Single Technology Path Can Trigger Systemic Risk

The San Diego biotech cluster in California once focused heavily on stem cell therapy. Around 2010, a large number of startups concentrated in this field.

However, as FDA regulations tightened—requiring full clinical trials under pharmaceutical standards—and multiple technologies failed to meet clinical expectations, the industry bubble quickly burst, leading to widespread financial distress among companies.

Implication: Veterinary pharmaceutical companies should maintain diversified product pipelines covering chemical drugs, biologics, traditional veterinary medicine, and feed additives to mitigate risks from technological shifts, regulatory changes, and market volatility.

2. Insufficient Industrial Chain Support Leads to Innovation “Islands”

Some emerging biotech parks, due to lack of long-term planning, heavily invest in front-end facilities such as laboratories while neglecting back-end infrastructure such as CDMOs, cold-chain logistics, third-party testing, and regulatory consulting.

As a result, although companies can conduct basic research, they struggle to scale up production or achieve commercialization, leading to a situation where “research results exist but no commercialization path is available.” Some parks ultimately become underutilized “empty zones” with low industrial vitality.

Implication: Veterinary export companies should choose partners with complete industrial chain capabilities to ensure end-to-end support from R&D to export.

3. Weak Intellectual Property Protection Limits Innovation Momentum

Taking India’s biopharmaceutical development as an example, before 2005, only process patents (rather than compound patents) were protected.

This limited protection led to a dominance of generic drug production and weak incentives for original drug innovation.

In 2005, India revised its patent law to comply with the WTO TRIPS Agreement, extending protection to pharmaceutical compounds, strengthening infringement enforcement, and promoting a shift from process imitation toward higher-value compliant supply, biosimilars, and innovative R&D.

Implication: A robust intellectual property protection system is the institutional foundation for sustainable innovation in veterinary pharmaceuticals. Export companies should prioritize patent strategies in target markets, clarify ownership boundaries, and pay attention to veterinary drug patent linkage systems and data exclusivity policies.